It’s hard for practicing oncologists to stay on top of the latest clinical data, but good partnerships and clinical decision ...
It’s time to acknowledge that we are “aware,” it’s time to rebrand October as the month for more relevant breast cancer ...
Biotech Nuvalent unveiled updates on two experimental cancer medicines over the weekend. Analysts say each could be the best ...
Bispecific antibodies and anti-TIGIT therapies both appear to be writing comeback stories as cancer experts head to Barcelona for the 2024 European Society for Medical Oncology Congress. Radioligand ...
Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its ...
Researchers from the universities of Zurich, Yale and Harvard reveal the differences between the characteristics of the ...
Westside Current on MSN4d
Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other ...SAN FRANCISCO and SUZHOU, China, Sept. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
The Medicaid Cancer Foundation (MCF), on behalf of the International Gynecologic Cancer Society (IGCS), has honored its CEO, ...
At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancerAt ...
Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on Mural Oncology Plc (MURA – Research Report) and keeping the price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback